(147 days)
No
The device description and performance studies focus on the topical cream's formulation and biological effects, with no mention of AI/ML or related technologies.
Yes
The device is indicated for the management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis, which are therapeutic uses.
No
The device is a cream indicated for the management (treatment) of dermatoses, not for their diagnosis. The descriptions focus on its formulation and clinical testing for safety and efficacy in treatment.
No
The device description clearly states it is a "fragrance-free, water-soluble dressing formulated for the management of various types of dermatoses" and is intended for "topical application." This describes a physical cream, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis." This describes a topical treatment for skin conditions.
- Device Description: The device is described as a "fragrance-free, water-soluble dressing formulated for the management of various types of dermatoses." It is intended for "topical application."
- Lack of IVD Characteristics: IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. This device does not involve the examination of such specimens.
The device is a topical cream intended for direct application to the skin for therapeutic purposes, which falls outside the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Indicated for the management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis
Product codes (comma separated list FDA assigned to the subject device)
FRO
Device Description
NEOCERA Advanced Cream is a fragrance-free, water-soluble dressing formulated for the management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis.
NEOCERA Cream is intended for topical application. This product is to be sold by prescription only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical testing
-
Cytotoxicity Agar Diffusion Report No. V15-2677 (see section 15. Biocompatibility -Page 312)
Cytotoxicity testing was performed under Good Laboratory Practice (GLP) Standards and per ISO 10993-5, part 5: Test for In Vitro Cytotoxicity. The testing demonstrated that NEOCERA cream meets the requirement of the test per ISO 10993-5, and therefore is not cytotoxic. -
Primary Dermal Irritation in Rabbits Report No. T15-1205-01 (see section 15. -Biocompatibility Page 312)
Irritation testing was performed under GLP standards and also according to ISO 10993-10. Biological Evaluation of Medical devices- Part 10: Test for Irritation and Sensitization. The test article, NEOCERA Cream Elicited a primary dermal irritation index of 0.67 on a scale of 0-8. A primary dermal irritation index of 0.67 is categorized as being slightly irritant. We would like to point out that slightly irritant category ranges from 0.5-1.9, and clearly the test article NEOCARA Cream is at the lower end of the range. -
Guinea Pig Closed Patch Sensitization Test Report No. T15-1205-2 (see section 15. Biocompatibility Page 313)
Sensitization testing was also performed under GLP standards and per ISO 10993-10. Biological Evaluation of Medical devices- Part 10: Test for Irritation and Sensitization. Under the conditions of the testing, the test article did not elicit a sensitization reactions in the guinea pigs.
Clinical testing
- Repeated Insult Patch Test in Humans Report No. C15-1204.01 (see section 15. -Biocompatibility Page 313)
This test was perform in accordance with the Declaration of Helsinki. ICH E6. and 21 CFR Parts 50 and 56. The test article NEOCERA Cream did not demonstrate any potential for dermal irritation or allergic contact sensitization in humans.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
K110727, K041342, K09156, K050158
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
Image /page/0/Picture/2 description: The image is a logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the circle is a stylized image of three human profiles facing to the right, with flowing lines representing hair or clothing.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 22, 2017
EXELTIS USA Dermatology, LLC Babu Lad Vice President of Regulatory Affair 180 Park Avenue. Suite 101 Florham Park, New Jersey 07932
Re: K170911
Trade/Device Name: NEOCERA Advanced Barrier Cream Regulatory Class: Unclassified Product Code: FRO Dated: March 23, 2017 Received: July 19, 2017
Dear Babu Lad:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
David Krause -S
for
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K170911
Device Name Neocera Advanced Cream
Indications for Use (Describe)
Indicated for the management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995,
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
July 2017 Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
3
5 510(k) K170911 Summary
As required by the Safe Medical Devices Act (SMDA) of 1990 and in accordance with 21 CFR 807.87(h) and (21 CFR 807.92a), the following summary is provided.
Submitter Information 5.1
| Owner's Name: | EXELTIS USA Dermatology, LLC |
|---|---|
| Address: | 180 Park Avenue, Suite 101 |
| Florham Park, NJ 07932 | |
| Phone: | (973) 324-0200 |
| Fax: | (973) 324-0795 |
Contact Person: Babu Lad, Vice President, Regulatory Affairs
Date of Summary Updated: August 22, 2017
4
5.2 Product Information
Product Trade Name: NEOCERA™ Advanced Cream
| Common Name: | Wound Dressing |
|---|---|
| Device Classification: | Unclassified |
| Product Code: | FRO |
Device Description
NEOCERA Advanced Cream is a fragrance-free, water-soluble dressing formulated for the management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis.
NEOCERA Cream is intended for topical application. This product is to be sold by prescription only.
Intended Use and Indications for Use
NEOCERA Cream is indicated for management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis.
Predicate Device
The chosen predicate device is Neosalus cream (K090585).
| NEOCERA | Predicate Neosalus | |
|---|---|---|
| Intended Use and Indication | ||
| for Use | Management of various | |
| types of dermatoses, | ||
| including atopic dermatitis | ||
| and allergic contact | ||
| dermatitis. | Management of various | |
| types of dermatoses, | ||
| including atopic dermatitis | ||
| and allergic contact | ||
| dermatitis. | ||
| Rx Only | Yes | Yes |
Technological Characteristics
NEOCERA Cream is a topical dressing. The chosen predicate device is Neosalus cream (K090585). The two product are very similar in terms of formulation and indication for use. Both device are non-sterile formulations intended for topical application and for prescription use only.
The formulation of NEOCERA Cream helps the product form a semi-occlusive dressing to cover the affected area of the body. The only difference in the formulations of the
Confidential and Proprietary EXELTIS USA Dermatology, LLC
5
NeoCera Advanced Cream 510(K) K170911
NEOCERA Cream and the predicate is the use of additional ingredients in the NEOCERA Cream formulation. These ingredients although new in the formulation, have been previously used in various cleared devices in the same category as NEOCERA Cream and the Predicate. The ingredients were added to enhance the ease of application. More information has been provided on the additional ingredients in section 10 of this 510 (k) submission (Executive Summary)
Comparison of technological Characteristics between NEOCERA Cream and the Predicate
| Technological
| Characteristics | NEOCERA | Neosalus |
|---|---|---|
| Topical Dressing | Same | Same |
| Composition | Similar to predicate | Similar |
| Skin conditioning agents to | ||
| enhance appearance of dry | ||
| skin | Present | None |
| Film Former | Present* | Present |
| Preservatives | Present | Present |
| Emulsifier | Present | Present |
- In higher quantity than in predicate (see Table 10.2, Page 32 of original submission)
6
| Comparison of NEOCERA Cream and Predicate Device Composition | |
|---|---|
| -------------------------------------------------------------- | -- |
| Ingredient | Function | NEOCERA | Neosalus | Medical
devices Use |
|-------------------------|-----------------------------------------------------|---------|----------|-----------------------------------------------------------------|
| Purified Water | Solvent | QS | QS | Predicate |
| Carbomer 980 | Thickening
agent | 0.7 | 0.7 | Predicate |
| Stearic Acid | Emulsifying
agent | 6.25 | 6.25 | Predicate |
| Glycerin | Humectant | 1.7 | 1.7 | Predicate |
| Propylene Glycol | Humectant | 5.8 | 5.8 | Predicate |
| Polysorbate 20 | Emulsifying
agent | 1.4 | 1.4 | Predicate |
| Plasdone | Film former | -- | 1.9 | Predicate |
| Triethanolamine | Emulsifying
agent and pH
buffer | 1 | 1.3 | Predicate |
| Phenonip XB | Preservative | 0.5 | 0.5 | Predicate |
| Sodium Hydroxide | pH adjuster | 0.008 | 0.2 | Predicate |
| Dimethicone@ | Film former | 5 | 0.95 | Predicate |
| Petrolatum | Film former | 5 | -- | Hylatopic
Plus Cream
(K110727) |
| Ceramide PC-104 * | Skin
conditioning
agent | 0.5 | -- | Hylatopic
Plus Cream
(K110727) |
| Palmitamide MEA | Viscosity
builder; Skin
conditioning
agent | 0.01 | -- | Mimyx
Cream
(K041342) |
| Glycerrhetinic Acid | Skin
conditioning
agent | 0.4 | -- | Pruclair
Cream
(K09156)
Promiseb
Cream
(K050158) |
| Grape seed
extract** | Antioxidant | 0.1 | -- | Pruclair
Cream
(K09156)
Promiseb
Cream
(K050158) |
@ Dimethicone is accepted for human use in OTC monograph from 1% to 30% [21 CFR 347.10 (g)] Petroleum and Ceramide
7
NeoCera Advanced Cream 510(K) K170911
Performance Data
The predicate device is a non-sterile formulation that is applied topically for the management and relief of irritation associated with various types of dermatoses. Non-clinical testing as well as clinical testing were conducted to establish that NEOCERA has a safety and biocompatibility profile similar to the predicate device.
Non-Clinical testing
-
Cytotoxicity Agar Diffusion Report No. V15-2677 (see section 15. Biocompatibility -Page 312)
Cytotoxicity testing was performed under Good Laboratory Practice (GLP) Standards and per ISO 10993-5, part 5: Test for In Vitro Cytotoxicity. The testing demonstrated that NEOCERA cream meets the requirement of the test per ISO 10993-5, and therefore is not cytotoxic. -
Primary Dermal Irritation in Rabbits Report No. T15-1205-01 (see section 15. -Biocompatibility Page 312)
Irritation testing was performed under GLP standards and also according to ISO 10993-10. Biological Evaluation of Medical devices- Part 10: Test for Irritation and Sensitization. The test article, NEOCERA Cream Elicited a primary dermal irritation index of 0.67 on a scale of 0-8. A primary dermal irritation index of 0.67 is categorized as being slightly irritant. We would like to point out that slightly irritant category ranges from 0.5-1.9, and clearly the test article NEOCARA Cream is at the lower end of the range. -
Guinea Pig Closed Patch Sensitization Test Report No. T15-1205-2 (see section 15. Biocompatibility Page 313)
Sensitization testing was also performed under GLP standards and per ISO 10993-10. Biological Evaluation of Medical devices- Part 10: Test for Irritation and Sensitization. Under the conditions of the testing, the test article did not elicit a sensitization reactions in the guinea pigs.
Clinical testing
- Repeated Insult Patch Test in Humans Report No. C15-1204.01 (see section 15. -Biocompatibility Page 313)
This test was perform in accordance with the Declaration of Helsinki. ICH E6. and 21 CFR Parts 50 and 56. The test article NEOCERA Cream did not demonstrate any potential for dermal irritation or allergic contact sensitization in humans.
8
Biocompatibility Sterilization and Shelf Life
| NEOCERA | Neosalus | |
|---|---|---|
| Biocompatibility (Non – | ||
| clinical and Clinical testing) | Similar | Similar |
| Sterilization | Non- Sterile | Non-Sterile |
| Antimicrobial Efficacy | ||
| Testing | Meet requirement | Meet requirement |
| Shelf Life | 24 months ( on going | |
| Stability) | 36 months |
Conclusion
Based on its formulation, indication for use, as well as the non-clinical and clinical testing results showing a similar safety profile, we conclude that NEOCERA Cream is substantially equivalent to its predicate device Neosalus cream.